openPR Logo
Press release

HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022

07-11-2017 12:26 PM CET | Health & Medicine

Press release from: Kuick Resarch

HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022

For Report Sample Contact: or +91-11-47067990

Report Table of Contents

Introduction to Human Immunodeficiency Virus (HIV) Vaccines
1.1 Overview
1.2 Antiquity of HIV Vaccine

Need for the Development of HIV Vaccine

Primer of HIV inside the Body
3.1 Inclusion of HIV Virus into the System
3.2 Interaction of HIV with Host
3.3 Eradication of HIV Virus

HIV Vaccine Development Process
4.1 Introduction
4.1.1 Classification of HIV Virus
4.1.2 Structure of HIV Virus
4.2 HIV Vaccine Construct Methodologies
4.2.1 Live Attenuated Vaccine
4.2.2 Synthetic Peptide Vaccines
4.2.3 Inactivated Vaccines
4.2.4 DNA Vaccine
4.2.5 Recombinant Vector Vaccine

Modified Approaches for HIV Vaccine Development
5.1 HIV Vaccine Expansion by Computer Aided Drug Design
5.2 Genetic Variety Attentions for Vaccine Design
5.3 Virus like Particles Approach for the HIV Vaccine Production
5.4 T-cell based Approach for HIV Vaccine

Prophylactic and Therapeutic HIV Vaccine
6.1 Prophylactic HIV Vaccine
6.1.1 Pre Exposure Prophylaxis
6.1.2 Post Exposure Prophylaxis (PEP)
6.2 Therapeutic HIV Vaccine

HIV Drugs Taxonomy and Resistance
7.1 Categorization of the Drugs
7.1.1 Nucleoside Analogue Reverse Transcriptase Inhibitors (NRTIs)
7.1.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
7.1.3 Protease Inhibitors
7.1.4 Fusion Inhibitors
7.2 Contrivance of HIV Drug Resistance
7.2.1 Resistance to Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
7.2.2 Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors
7.2.3 Resistance to Protease Inhibitors
7.2.4 Resistance to Fusion Inhibitors

Decisive Factors for Commercialization of HIV Vaccines
8.1 Efficacy
8.2 Controlled Transmission
8.3 Relapse
8.4 Economical
8.5 Manufacturing Scalability

Global HIV Vaccine Market Outlook
9.1 Overview
9.2 Current Market Scenario
9.3 Incidence and Prevalence
9.4 Funding Scenario for HIV Vaccine

Global HIV Vaccine Clinical Pipeline Overview

Global HIV Vaccine Market Dynamics
11.1 Favorable Market Parameters
11.2 Commercialization Challenges

Global HIV Vaccine Market Future Outlook

Global HIV Vaccine Clinical Pipeline by Company, Indication and Phase
13.1 Research
13.2 Preclinical
13.3 Clinical
13.4 Phase-I
13.5 Phase-I/II
13.6 Phase-II
13.7 Phase-III
13.8 Preregistration

Competitive Landscape
14.1 AlphaVax
14.2 Antigen Express
14.3 Argo Therapeutics
14.4 Bionor Pharmaceuticals
14.5 Celldex Therapeutics
14.6 FIT Biotech
14.7 Crucell Pharmaceutical
14.8 GeneCure
14.9 Genetic Immunity
14.10 GenVec
14.11 GeoVax Labs
14.12 Glaxo Smithkline
14.13 Immune Response BioPharma
14.14 Inovio Pharmaceuticals
14.15 Novartis
14.16 Oncolys Biopharma
14.17 PaxVax
14.18 Profectus Biosciences
14.19 Sanofi
14.20 TVAX Biomedical

Download Report:

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release HIV Vaccine Market HIV Vaccine Clinical Pipeline Report 2022 here

News-ID: 618689 • Views: 281

More Releases from Kuick Resarch

Global CFTR Modulators Market Opportunity Clinical Trials Insight 2026
“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights: • Global CFTR Modulators Market Opportunity: > US$ 20 Billion • Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020) • Global CFTR Modulators Market Growth In 2020: 55% • Global CFTR Modulators Pipeline: 30 Drug • Commercially Available Bispecific Antibodies: 4 Drugs • Trikafta Market Share 2020: > 50% Download Report: “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides
Gamma Delta T Cell Cancer Therapy Opportunity Clinical Trials Insight 2026
“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights: • Commercialization Market Potential After Market Launch: > USD 4 Billion • Insight on Key Drugs In Research & Development • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight • Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type • Adopted Approaches for Gamma Delta T Cell Therapy Download
Global Peptide Drug Conjugate Clinical Trial Report 2026
Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: • First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide) • Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast • Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea • Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs • Clinical Trials Insight by Company, Country, Indication • Patent Insight of Peptide Drug Conjugates • Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Download Report: “Global Peptide
Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024
"Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights: • Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion • Trispecific Antibodies In Clinical Trials: > 8 Antibodies • Highest Phase of Development: Phase I/II • Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies • Numab Therapeutics Dominating the Trispecific Development Pipeline • Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies Download Report: Trispecific cancer antibody therapy market at

All 5 Releases

More Releases for HIV

Global HIV Market to 2024
The HIV market was valued at $16bn in 2015 and is forecast to expand at a CAGR of 3.7% between 2015 and 2024, culminating in 2024 global sales of $23bn.The expected arrival of new classes of therapies could result in a paradigm shift in the treatment of HIV treatment. Globally, around 35 million people are infected with HIV. Approximately 3 million people in the U.S and 2.5 million in top 5
Global HIV Vaccine Market & HIV Vaccine Clinical Trial Outlook 2022
Worldwide, around the 35 Million of the people are currently infected with the HIV and about 30 Million of the people died because of the AIDS infection. There is no human example of clearing an HIV infection naturally. HIV virus makes copies of it very quickly, many types of HIV exist and new types of virus are continue to rise. Many scientists are still trying to understand the specific ways
Global HIV Infection Pipeline Analysis
The discovery of HIV virus, which causes AIDS, dates back to more than 30 years. Currently, there are more than 30 drugs in the market which have been approved by the FDA for the treatment of HIV infection. Consequent to the introduction of retrovirals in 1996, HIV is not considered to be a death sentence anymore. The advancements in this field have led to new drugs being produced which have
Global HIV Therapeutics Market
The HIV Therapeutics Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. The human immunodeficiency virus (HIV) refers to a type of retrovirus that causes acquired immunodeficiency syndrome (AIDS). HIV attacks some immune cells and causes weakness of immune system resulting in loss
Hidden HIV Revealed: New Insights Into Latent HIV Infections
In spite of ever more effective therapies, HIV keeps managing to survive in the body. A comprehensive project conducted by the Austrian Science Fund FWF has clarified the molecular processes which contribute to this effect. In the process, approaches were discovered for possible therapies to combat the hidden reservoir formed by the virus. Thanks to modern therapies, HIV infections have become controllable – but these treatments cannot provide a cure. Antiretroviral
Approaches to HIV Eradication
The various approaches to HIV eradication all address a problem, and that problem is the HIV reservoir. HIV reservoirs have been called the last hiding place for HIV within the body. The final step toward finding a cure against HIV lies in dealing with HIV reservoirs. Toulon, France, August 30, 2011 - What can be done about HIV eradication? The advancements in scientific technology and medical treatments have made significant progress